Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ACADEMIA
ACADEMIA
- Diovan Paper Contained “Careless Errors,” but “No Impact on Findings”: Chief Investigator Comments on Retraction
February 7, 2013
- JSGM Calls for 80% Generic Share, 30% Reduction in NHI Prices of Long-Listed Drugs by End of FY2017
December 6, 2012
- Less than 20% of IRBs Utilize Central IRB Despite Revised GCP Ordinance: Dr Narumoto of Okayama Univ.
December 5, 2012
- Need for Corporate Seminars May Depend on “Doctors’ Abilities”: NIRS Senior Researcher Kurihara
November 30, 2012
- AASD Scientific Meeting Shines Light on SGLT-2 Inhibitors as Next Generation Diabetes Treatment
November 28, 2012
- New Hoshi General Hospital to Give Patients Option of In-House or Legal Prescriptions Starting in January
November 22, 2012
- J-ADNI2 to Go Forward in Search of New Treatment for AD: Prof. Iwatsubo of Univ. of Tokyo
November 19, 2012
- New COPD GLs to Recommend LAMA, LABA Equally: Prof. Nagai of Tokyo Women’s Medical University
October 22, 2012
- Biosimilars Should Be Mentioned in Government Roadmap: JSGM President Muto
October 18, 2012
- Supercomputer to Dramatically Shorten Exploratory Period for Lead Compounds: Prof. Fujitani of University of Tokyo
October 16, 2012
- We Would Like to Provide iPS Cells with Medical History Identification: Prof. Yamanaka of Kyoto University
October 15, 2012
- JAOG Insists on Introduction of HPV Testing to Cervical Cancer Screening
September 14, 2012
- CRND Initiates Clinical Research, Showing Willingness for Company-Sponsored Studies
September 6, 2012
- Incidence of CVD Decreases More in High-Risk Patients with Lower LDL-C during Pravastatin Treatment
July 26, 2012
- 95% of Japanese-Bound Online Drug Sales “Rogue”: LegitScript Survey
July 26, 2012
- Takeda’s TAK-070 for AD Worthy of Clinical Trial: Prof. Iwatsubo of Univ. of Tokyo Hospital
July 18, 2012
- Inlyta Can Be 1st-Choice in 2nd-Line Therapy: Prof. Uemura of Kinki Univ.
July 13, 2012
- Minirinmelt Most Effective for Nocturnal Enuresis, But Precaution for Water Intoxication Needed: Prof. Kaneko
July 11, 2012
- Drug Damage Watchdog Calls for Halt to Easing of Safety Management Procedures for Thalidomide
June 28, 2012
- Univ. of Tokyo Hospital’s New “Phase I Unit” to Initiate Trials for Takeda’s TAK-070 for AD
June 28, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…